Understanding intravenous leiomyomatosis causes and risk factors
Part of Infections clinical trials.
This study looks at why some women develop intravenous leiomyomatosis (IVL), a rare condition where non-cancerous uterine tumors grow into veins. By studying tissue samples and medical data, researchers hope to find better ways to diagnose and treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (18 or older).
- You are scheduled for surgery at Peking Union Medical College Hospital (PUMCH) for a suspected uterine fibroid or IVL.
- You do not have another active cancer.
- You are not pregnant or breastfeeding.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different types of HPV infections might affect overall health and disease outcomes. By participating, you'll help researchers understand more about the long-term risks associated with HPV, which could lead to better screening and prevention strategies.
This study looks at how having multiple types of HPV virus affects the development of abnormal cervical cells (called CIN). It may help doctors understand why some people are more at risk and could lead to better prevention.
This trial looks at whether taking a small tissue sample (biopsy) before surgery can help doctors better understand unusual uterine growths that look like fibroids. If you're already planning surgery to remove such a growth, this study might help guide your treatment.
This study looks at tumor samples from people with certain cancers to compare those caused by viruses (like HPV, HIV, or EBV) with those not caused by viruses. The goal is to understand why some tumors respond differently to treatments, which may help improve future treatment approaches.
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.